Akebia Therapeutics, Inc. (AKBA)
0.865
-0.01
(-0.69%)
USD |
NASDAQ |
Oct 02, 16:00
0.85
-0.02
(-1.73%)
After-Hours: 20:00
Akebia Therapeutics Net Income (Quarterly) : -8.908M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.908M |
| March 31, 2026 | -9.054M |
| December 31, 2025 | -12.24M |
| September 30, 2025 | 0.54M |
| June 30, 2025 | 0.247M |
| March 31, 2025 | 6.112M |
| December 31, 2024 | -22.80M |
| September 30, 2024 | -20.04M |
| June 30, 2024 | -8.582M |
| March 31, 2024 | -17.98M |
| December 31, 2023 | 0.613M |
| September 30, 2023 | -14.49M |
| June 30, 2023 | -11.17M |
| March 31, 2023 | -26.88M |
| December 31, 2022 | -9.216M |
| September 30, 2022 | -54.10M |
| June 30, 2022 | 29.45M |
| March 31, 2022 | -62.42M |
| December 31, 2021 | -69.86M |
| September 30, 2021 | -59.54M |
| June 30, 2021 | -83.04M |
| March 31, 2021 | -69.58M |
| December 31, 2020 | -87.00M |
| September 30, 2020 | -59.96M |
| June 30, 2020 | -175.75M |
| Date | Value |
|---|---|
| March 31, 2020 | -60.75M |
| December 31, 2019 | -94.48M |
| September 30, 2019 | -54.58M |
| June 30, 2019 | -58.17M |
| March 31, 2019 | -72.42M |
| December 31, 2018 | -60.05M |
| September 30, 2018 | -26.05M |
| June 30, 2018 | -34.07M |
| March 31, 2018 | -23.42M |
| December 31, 2017 | 15.52M |
| September 30, 2017 | -23.13M |
| June 30, 2017 | -21.52M |
| March 31, 2017 | -44.54M |
| December 31, 2016 | -37.86M |
| September 30, 2016 | -36.31M |
| June 30, 2016 | -35.78M |
| March 31, 2016 | -25.80M |
| December 31, 2015 | -19.86M |
| September 30, 2015 | -19.48M |
| June 30, 2015 | -10.69M |
| March 31, 2015 | -10.70M |
| December 31, 2014 | -10.37M |
| September 30, 2014 | -9.348M |
| June 30, 2014 | -7.618M |
| March 31, 2014 | -96.60M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Emergent BioSolutions, Inc. | -180.20M |
| Exelixis, Inc. | 212.05M |
| ADMA Biologics, Inc. | 37.82M |
| Arcutis Biotherapeutics, Inc. | 15.01M |
| Relay Therapeutics, Inc. | -83.71M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 49.13M |
| Total Expenses (Quarterly) | 58.04M |
| EPS Diluted (Quarterly) | -0.033 |
| Enterprise Value | 288.61M |
| Gross Profit Margin (Quarterly) | 77.59% |
| Profit Margin (Quarterly) | -18.13% |
| Earnings Yield | -12.83% |
| Normalized Earnings Yield | -13.69 |